Genenta Science (GNTA) Competitors $5.01 -0.35 (-6.53%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNTA vs. CYRX, PROC, NGNE, BTMD, DSGN, VYGR, CTNM, KMDA, SLRN, and CGCShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Cryoport (CYRX), Procaps Group (PROC), Neurogene (NGNE), biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Kamada (KMDA), Acelyrin (SLRN), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Cryoport Procaps Group Neurogene biote Design Therapeutics Voyager Therapeutics Contineum Therapeutics Kamada Acelyrin Canopy Growth Cryoport (NASDAQ:CYRX) and Genenta Science (NASDAQ:GNTA) are both small-cap transportation companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings. Which has more risk & volatility, CYRX or GNTA? Cryoport has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Is CYRX or GNTA more profitable? Genenta Science has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Genenta Science's return on equity of 0.00% beat Cryoport's return on equity.Company Net Margins Return on Equity Return on Assets Cryoport-70.08% -13.35% -6.43% Genenta Science N/A N/A N/A Does the MarketBeat Community prefer CYRX or GNTA? Cryoport received 235 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 65.05% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformCryoportOutperform Votes24265.05% Underperform Votes13034.95% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% Do analysts prefer CYRX or GNTA? Cryoport currently has a consensus target price of $12.29, suggesting a potential upside of 56.31%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 399.00%. Given Genenta Science's stronger consensus rating and higher possible upside, analysts plainly believe Genenta Science is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, CYRX or GNTA? Genenta Science has lower revenue, but higher earnings than Cryoport. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoport$226.11M1.72-$99.59M-$3.38-2.33Genenta ScienceN/AN/A-$12.60MN/AN/A Does the media favor CYRX or GNTA? In the previous week, Cryoport had 2 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Cryoport and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.05 beat Cryoport's score of 0.97 indicating that Genenta Science is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genenta Science 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of CYRX or GNTA? 92.9% of Cryoport shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 10.1% of Cryoport shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryGenenta Science beats Cryoport on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.63M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7389.8217.18Price / SalesN/A415.011,116.21116.95Price / CashN/A182.1042.8937.86Price / Book4.143.894.784.78Net Income-$12.60M-$42.21M$120.23M$225.60M7 Day Performance-2.34%-2.15%-1.92%-1.23%1 Month Performance4.38%4.20%11.49%3.36%1 Year Performance-0.71%18.39%30.57%16.60% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.961 of 5 stars$5.01-6.5%$25.00+399.0%+0.2%$91.63MN/A0.007News CoverageGap UpCYRXCryoport3.0208 of 5 stars$7.65-0.5%$12.50+63.4%-49.8%$378.15M$226.11M-2.321,170Analyst ForecastGap DownPROCProcaps Group0.8826 of 5 stars$3.31+37.3%N/A-20.3%$373.43M$414.10M5.105,500News CoverageHigh Trading VolumeNGNENeurogene3.7408 of 5 stars$24.67+4.9%$60.83+146.6%N/A$366.47M$925,000.000.0090BTMDbiote3.0893 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpDSGNDesign Therapeutics0.9221 of 5 stars$6.29+12.3%$7.00+11.3%+143.2%$356.15MN/A-7.1840News CoveragePositive NewsVYGRVoyager Therapeutics4.6114 of 5 stars$6.50+3.7%$17.00+161.5%-27.6%$355.10M$250.01M8.83100CTNMContineum Therapeutics1.9558 of 5 stars$13.68-2.5%$29.25+113.8%N/A$352.67M$50M0.0031News CoverageKMDAKamada3.8909 of 5 stars$5.85-0.3%$14.50+147.9%-1.2%$336.26M$158.38M20.96360Positive NewsSLRNAcelyrin2.7884 of 5 stars$3.34+3.4%$11.75+251.8%-55.8%$335.10MN/A-1.31135CGCCanopy Growth2.4368 of 5 stars$3.07-1.3%$3.50+14.0%-41.0%$334.45M$220.27M-0.631,029Analyst RevisionNews Coverage Related Companies and Tools Related Companies Cryoport Competitors Procaps Group Competitors Neurogene Competitors biote Competitors Design Therapeutics Competitors Voyager Therapeutics Competitors Contineum Therapeutics Competitors Kamada Competitors Acelyrin Competitors Canopy Growth Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNTA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
